Meet us next:   BIO International Convention 2025 – 4 September  ●  NIH Research Festival Vendor Exhibit – 10 September  ●  ELRIG – Drug Discovery in Scotland 2025 – 17 September  ●  The Cell & Gene Meeting on the Mesa 2025 – 6-8 October (in person) & 9-10 October (virtual)  ●  ELRIG – Drug Discovery – 21-22 October  ●  more on our events calendar

Recombinant human TPO protein

QK098

Brand: Qkine

Thrombopoietin (TPO) is a cytokine which stimulates the production and differentiation of megakaryocytes, regulating platelet production. Recombinant TPO can be used to support the self-renewal and maintenance of hematopoietic stem cells.

Qkine TPO is a 16 kDa protein, animal origin-free, tag-free and carrier it has been manufactured to be highly pure and bioactive for reproducible hematopoietic stem cell culture.

Currency: 

Product name Catalog number Pack size Price Price (USD) Price (GBP) Price (EUR)
Recombinant human TPO protein, 25 µg QK098-0025 25 µg (select above) $ 315.00 £ 255.00 € 263.00
Recombinant human TPO protein, 50 µg QK098-0050 50 µg (select above) $ 515.00 £ 380.00 € 444.00
Recombinant human TPO protein, 100 µg QK098-0100 100 µg (select above) $ 760.00 £ 560.00 € 655.00
Recombinant human TPO protein, 500 µg QK098-0500 500 µg (select above) $ 3,100.00 £ 2,300.00 € 2,687.00
Recombinant human TPO protein, 1000 µg QK098-1000 1000 µg (select above) $ 4,950.00 £ 3,600.00 € 4,205.00

Note: prices shown do not include shipping and handling charges.

Qkine company name and logo are the property of Qkine Ltd. UK.

Alternative protein names

Thyroid Peroxidase, TPX, Thyroid Microsomal Antigen, Thyroperoxidase, TDH2A, Thrombopoietin, THPO, MPL ligand, megakaryocyte colony-stimulating factor, MGDF, Qk98

Species reactivity

human

Species similarity:
  • mouse - 92%
  • rat - 91%
  • bovine - 85%
  • porcine - 91%

Summary

  • High purity human protein (Uniprot: P40225)
  • 16 kDa (monomer)
  • >98%, by SDS-PAGE quantitative densitometry
  • Expressed in E. coli
  • Animal origin-free (AOF) and carrier protein-free
  • Manufactured in Qkine'sCambridge, UK laboratories
  • Lyophilized from acetonitrile, TFA
  • Resuspend in 10 mM HCl (Reconstitution solution A) at >50 µg/ml, add carrier protein if desired, prepare single-use aliquots and store frozen at -20 °C (short-term) or -80 °C (long-term)

Handling and Storage FAQ

Featured applications

  • Differentiation of myeloid progenitors into erythrocytes and megakaryocytes
  • Differentiation of stem cells into erythrocytes and megakaryocytes
  • Maintenance and differentiation of hematopoietic stem cells

Bioactivity

Recombinant TPO activity was determined using a Promega serum response element luciferase reporter assay in HEK293T cells co-transfected with TPOR. Cells were treated in triplicate with a serial dilution of TPO for 3 hours. Firefly activity was measured and normalized to the control Renilla luciferase activity. Data from Qk098 lot 204752. EC50 = 4.72 ng/ml (0.30 pM).

Qk098-TPO-human-graph-800

Purity

Recombinant TPO migrates at approximately 14 kDa (monomer) in reduced (R) and non-reduced (NR) conditions. No contaminating protein bands are present. The purified recombinant protein (3 µg) was resolved using 15% w/v SDS-PAGE in reduced (+β-mercaptoethanol, R) and non-reduced (NR) conditions and stained with Coomassie Brilliant Blue R250. Data from Qk098 lot #204752.

20250724-Qk098-TPO-SDS-PAGE-800

Further quality assays

  • Mass spectrometry: single species with expected mass
  • Recovery from stock vial:  >95%
  • Endotoxin: <0.005 EU/μg protein (below level of detection)

Protein background

TPO is a class I hematopoietic cytokine encoded by a gene located on chromosome 3q26-27. The TPO protein consists of 355 amino acids with the first 155 being homologous to erythropoietin (EPO) [1]. TPO binds to its receptor, Mpl and regulates proliferation and maturation of megakaryocytes as well as platelet production [1, 2].

TPO is primarily synthesized in the liver but can also be produced by the kidney, spleen, and bone marrow. In the liver, its production is constitutive and not linked to anemia like its homolog EPO [2]. Reduced platelet production leads to thrombocytopenia, a common hematological disorder which can lead to spontaneous bleeding, frequently as a side effect of cancer treatment [4, 5]. Severe cases may require a platelet transfusion [4]. However, the use of recombinant TPO as a treatment for thrombocytopenia has been investigated and has shown to increase platelet count [5].

TPO can also be used in the culture and differentiation of hematopoietic stem cells (HSCs) for research and therapeutic applications. TPO can support ex vivo expansion of HSC in combination with Flt3L and SCF [2]. In addition, it also increases the number of erythroid and myeloid progenitors, in synergy with stem cell factor (SCF) and interleukin-3 (IL-3) [3].

The TPO receptor Mpl is expressed primarily on megakaryocytes and platelets. TPO binding to Mpl causes receptor dimerization and phosphorylation by JAK2. This activates multiple downstream signaling pathways including STATs, the MAPK pathway, and the PI3K pathway [2].

Background references

  1. Foster DC, Sprecher CA et al. Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1994. doi: 10.1073/pnas.91.26.13023.

  2. de Graaf CA, Metcalf D. Thrombopoietin and hematopoietic stem cells. Cell Cycle. 2011. doi: 10.4161/cc.10.10.15619.

  3. Kobayashi M, Laver JH et al. Thrombopoietin Supports Proliferation of Human Primitive Hematopoietic Cells in Synergy with Steel Factor and/or Interleukin-3. Blood 1996. https://doi.org/10.1182/blood.V88.2.429.bloodjournal882429.

  4. Wörmann B. Clinical indications for thrombopoietin and thrombopoietin-receptor agonists. Transfus Med Hemother. 2013. doi: 10.1159/000355006.

  5. Vadhan-Raj S, Murray LJ et al. Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer. Ann Intern Med.1997. doi:10.7326/0003-4819-126-9-199705010-00001.

FAQ

  1. What is TPO?
    Thrombopoietin or TPO is a cytokine produced by the liver and kidney and regulates the production of platelets.
  2. Where is TPO found?
    TPO is primarily produced in the liver and kidney and is found in circulating plasma.
  3. Is TPO a cytokine?
    Yes, Thrombopoietin (TPO) is a cytokine and is also classed as a hormone.
  4. What does TPO bind to?
    TPO binds to the myeloproliferative leukemia protein (MPL) or Cluster of Differentiation 110 (CD110), also known as the thrombopoietin receptor (TPO-R).
  5. What is the function of the TPO receptor?
    The TPO receptor MPL plays a crucial role in hematopoiesis, particularly in the development of megakaryocytes and platelets.
  6. What is the TPO pathway?
    Binding of TPO to its receptor, MPL (CD110), initiates a signaling cascade via JAK/STAT, MAPK, and PI3K/AKT signaling pathways that leads to the proliferation and differentiation of megakaryocytes and, ultimately, to the production of platelets (thrombopoiesis).